Active Ingredient(s):Cabazitaxel FDA Approved: * June 17, 2010 Pharm Company: *SANOFI AVENTIS US Category:Cancer
Cabazitaxel, sold under the brand name Jevtana, is a semi-synthetic derivative of a natural taxoid. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Cabazitaxel was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. It...
* May have multiple approval dates, manufacturers, or labelers. 2 Discussions